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In Brief Truong et al. elucidate the molecular mechanism underlying redox activation of EGFR. Sulfenylation of C797 activates EGFR kinase through new electrostatic interactions, which may induce a favorable change in catalytic loop dynamics. Furthermore, C797 sulfenylation and H 2 O 2 stress affects the pharmacology of covalent, thiol-targeted EGFR inhibitors.
INTRODUCTION
Epidermal growth factor receptor (EGFR) is one of the most studied receptor tyrosine kinases (RTKs) and serves as a quintessential model for understanding RTKs in physiological signaling (Schlessinger, 2000) , and has generated significant interest as a target for cancer therapeutics (Shawver et al., 2002) . EGFR is a member of the ErbB family of growth factor receptors (EGFR, Her2, Her3, and Her4) , and at least ten ligands are known to bind and activate family members (Bogdan and Klambt, 2001) . Ligand binding to the extracellular domain results in receptor dimerization with the same or different family members, autophosphorylation, kinase activation, and the generation of binding sites for various intracellular proteins that regulate cellular processes such as proliferation, survival, motility, adhesion, invasion, and angiogenesis. Elevated levels, mutation, and constitutive activation of EGFR are common features of many cancer types and promote tumor development by driving cell proliferation and survival (Blume-Jensen and Hunter, 2001 ). Consequently, numerous modalities, including antibodies to the extracellular domain of the receptor and small-molecule inhibitors that reversibly or irreversibly bind to the intracellular kinase domain (Hubbard, 2005) , have been developed to target EGFR and are currently in various stages of pre-clinical evaluation and clinical use (Wu et al., 2015) .
Ligand-mediated activation of RTKs, including EGFR, also leads to production of endogenous hydrogen peroxide (H 2 O 2 ) by membrane-bound NADPH oxidases (NOXs) (Brewer et al., 2015; Holmstrom and Finkel, 2014) . Receptor activation triggers rapid activation of NOX multiprotein complexes that catalyze the reduction of molecular oxygen (O 2 ) using cytosolic NADPH to generate superoxide (O 2 d- ) and its subsequent dismutation product, H 2 O 2 (Dickinson and Chang, 2011) . Once formed, H 2 O 2 transmits the redox signal via oxidation of cysteine residues in reactive sensor proteins, with concomitant modulation of biological function (Paulsen and Carroll, 2013; Veal et al., 2007) . In this way, H 2 O 2 serves as a second messenger in growth factor-induced signaling cascades. Reaction of cysteines with H 2 O 2 occurs solely with the thiolate anion (Cys-S -), and the direct product of this reaction, also referred to as S-sulfenylation, is sulfenic acid (Cys-SOH) (Chouchani et al., 2016; Dotsey et al., 2015; Finkel, 2012; Lo Conte and Carroll, 2013) . The oxidation and reduction of cysteine residues presents a mechanism to rapidly and reversibly alter activity, stability, localization, and proteinprotein interactions.
Using a selective, cell-permeable probe for detecting sulfenic acid, known as DYn-2, we have previously demonstrated that EGF-mediated signaling events induce dynamic changes in global protein S-sulfenylation, concurrent with changes in intracellular H 2 O 2 . Our study also revealed that ligand-induced EGFR activation resulted in NOX2-dependent sulfenylation of a cysteine residue (C797; Figure 1A ) at the hinge region of the catalytic ATP-binding pocket and that this modification was associated with enhanced tyrosine kinase activity. Sequence alignment shows that ten other kinases possess a cysteine at the same structural position as C797 of EGFR . These kinases include members of the Erb family (Her2 and Her4), the Tec family (BMX, BTK, ITK, TEC, and TXK), one Src member (BLK), MKKa7, and JAK3. Proximity to the catalytic pocket and selective oxidation strongly support an important regulatory function for sulfenylation of C797 (Heppner and van der Vliet, 2015; Truong and Carroll, 2013) ; however, the precise molecular mechanism for redoxbased activation of EGFR remains entirely unknown. It is critical to address both from a fundamental perspective and owing to implications for related kinases.
EGFR kinase domain mutations have been identified as a cause of non-small cell lung cancer (NSCLC), and the two most frequent include the exon-19 point mutation (L858R) and the exon-19 deletion (D746-750) ( Figure 1A ). L858R is the single most common mutation ($40%) and resides as part of the kinase activation loop (A loop). The L858R mutation causes constitutive activation of EGFR by destabilizing the autoinhibitory conformation of the A loop, which is its normal state in the absence of ligand (Yun et al., 2007; . Cells bearing this EGFR mutation exhibit decreased ATP affinity and are generally more sensitive to ATP-competitive inhibitors compared with cells expressing wild-type EGFR (Lynch et al., 2004) . Approximately one-half of lung cancer patients harboring the L858R mutation eventually develop resistance to ATP-competitive EGFR inhibitors due to a second-site mutation (T790M) (Kobayashi et al., 2005) . Residue 790 is located at the posterior of the ATP-binding pocket and is important for inhibitor binding and specificity. Although these activating mutations are often observed in human tumors, it is not known whether these kinases undergo cysteine oxidation and, if so, whether they exhibit a different redox sensitivity compared with wild-type EGFR.
Since the early 1990s, EGFR C797 has been targeted for therapeutic intervention with the objective of developing covalent irreversible inhibitors for the treatment of cancer (Liu et al., 2013) . These small-molecule inhibitors generally incorporate a Michael acceptor (electrophile warhead) to covalently modify EGFR C797 (nucleophile target) and a binding element specific for the kinase active site. Examples include Food and Drug Administration-approved afatinib ( Figure 1B ) as well as neratinib, dacomitinib, and rociletinib, currently in phase III clinical trials. In addition to modulation of EGFR kinase activity, sulfenylation of C797 has the potential to affect drug potency in two significant ways. Most obviously, variation in the redox state of Cys797 (e.g., -SOH, -SO 2 H, -SSG) can give rise to local conformational changes, which can affect the reversible binding affinity of EGFR inhibitors. Not quite so obvious, but equally important, is that oxidation of the cysteine g-sulfur blunts its nucleophilic reactivity . The aforementioned inhibitors all incorporate an acrylamide electrophile that undergoes facile reaction with the nucleophilic cysteine thiol group. The same reaction, however, does not take place with cysteine sulfenic acid, where the electrophilic reactivity of the g-sulfur is dominant in the aqueous physiological environment. S-Sulfenylation is a 
EGFR Catalytic Kinase Domain and Covalent Inhibitors
(A) Crystal structure of the EGFR kinase domain (PDB: 3VJO) bound to AMP-PNP showing all six conserved cysteine residues. The catalytic loop is highlighted in lime green, T790/L858 residues in magenta, and E746/A750 residues in lilac. (B) Top: structure of two electrophilic covalent EGFR inhibitors, afatinib and PD168393. The acrylamide functional groups in each inhibitor are highlighted in the gray circle. Bottom: crystal structure of the EGFR kinase domain (PDB: 4G5J) in a covalent thioether bond with afatinib at C797. dynamic and reversible process, involving the glutathione (GSH) and/or thioredoxin systems. Even so, chronic H 2 O 2 stress, such as that encountered in cultured malignant cells and solid tumors, would be expected to increase the steady-state population of oxidized cysteine residues. A key question, therefore, is whether chronic oxidative stress yields a population of EGFR that is refractory to C797-targeted irreversible drugs.
RESULTS
H 2 O 2 Activates Native EGFR through a Direct and Reversible Mechanism Our work and that of others has shown that moderate exogenous or endogenous H 2 O 2 elevation can lead to a net increase of EGFR autophosphorylation in cells (reviewed in Corcoran and Cotter, 2013; Heppner and van der Vliet, 2015; Truong and Carroll, 2012) . Using recombinant glutathione S-transferase (GST)-tagged EGFR kinase domain with a peptide-based assay, we have demonstrated that sulfenylation of C797 enhances the intrinsic tyrosine kinase activity . However, the impact of sulfenylation on the autophosphorylation activity of purified full-length EGFR has not been investigated. Thus, we isolated native EGFR from A431 cells by immunoprecipitation and assayed for its ability to autophosphorylate tyrosine residues within its cytoplasmic domain (Figures 2A and 2B) . Control experiments indicated that EGFR kinase activity increased nearly 2-fold after EGF treatment, congruent with findings from other groups (Cohen et al., 1980) . Next, we investigated whether H 2 O 2 treatment of native EGFR would also lead to an increase in receptor autophosphorylation. From 1 to 10 mM H 2 O 2 a dosedependent increase in EGFR kinase activity was observed, with a maximal stimulation of 3-fold. Importantly, reduction with DTT totally abrogated the enhancing effect of H 2 O 2 on kinase activity, consistent with sulfenic acid formation ( Figures  2A and 2B ). Site-specific generation of cysteine sulfenic acid (A) Full-length native EGFR was treated with EGF (3.3 ng/ml) or H 2 O 2 (0-100 mM). Western blot shows autophosphorylated (p) and total EGFR. (B) Densitometric quantification of (A). Data are normalized to untreated control and are representative of three independent readings (mean ± SEM). *p < 0.05, **p < 0.01, ***p < 0.001 compared with untreated control. (C) Bromobimane fluorescence labeling of recombinant EGFR over a pH range (2-6.5) yields a single pK a value for C797 of 5.5 ± 0. under these conditions was further supported by the observation of dimedonelabeled C797 by peptide mapping using liquid chromatography-tandem mass spectrometry (MS) (Figure S1 ). Indeed, tandem MS analysis including all oxidizable cysteine residues in the kinase domain ($95% overall amino acid sequence coverage) verified that oxidation occurs exclusively at C797, consistent with our earlier findings and as confirmed by Schwartz et al. (2014) . At H 2 O 2 levels greater than 25 mM, the enzymatic activity of EGFR began to decrease, likely through formation of sulfinic acid (-SO 2 -), which is known to reduce the fraction of functional active sites in EGFR (Schwartz et al., 2014) . Control experiments confirmed that pre-treatment of native EGFR with the irreversible inhibitor afatinib completely inhibited autophosphorylation, as expected (Figures 2A and 2B) . Coupled with our earlier findings that sulfenylation of C797 enhances catalytic activity with GSTtagged EGFR kinase domain in a peptide assay, these new data show that exposure to physiological concentrations of H 2 O 2 enhances autophosphorylation of native EGFR by reversible sulfenylation.
The Physical Properties of EGFR C797 Solvent accessibility and cysteine reactivity (modulated by pK a and microenvironment) are generally considered as the most important factors underlying thiol redox reactions. Consistent with this hypothesis, C797 has the greatest solvent-accessible surface area of any cysteine in the EGFR kinase domain (as calculated by GETAREA [Fraczkiewicz and Braun, 1998 ] four are buried: C781, C818, C929, and C950; C775 is somewhat solvent exposed, but with $10-fold less accessible area than C797; Figure 1A) . In addition, C797 is distinguished from all other cysteine residues in this domain by virtue of its location at the N terminus of an a helix (referred to the N cap position). Owing to the a-helix dipole, pK a perturbations significantly below the intrinsic thiol pK a ($8.3) are well documented at the N cap position (Anderson and Sauer, 2003; Miranda, 2003) . Since thiolates are significantly stronger nucleophiles than thiol groups and C797 preferentially reacts with H 2 O 2 , we hypothesized that this residue should exhibit a pK a value lower than the unperturbed value of 8.5. To test this proposal, we determined the pK a of C797 by its reactivity with the fluorescent thiol alkylating agent, monobromobimane, over a range of pH values. Using this method, the pK a value of C797 was determined to be 5.5 ± 0.1 ( Figure 2C ), approximately three orders of magnitude lower than the pK a of free sulfhydryl in solution. Pre-treatment with the irreversible C797-targeted inhibitor, PD168393 (Fry et al., 1998) , suppressed fluorescence labeling as expected. Finally, we measured the reactivity of EGFR C797 with H 2 O 2 . Since a thiol or thiolate is unreactive with sulfenic acid probe, DYn-2, the increase in reaction rate with this reagent as H 2 O 2 increases reports on reactivity of the target residue. Using this technique, a lower limit (imposed by further oxidation to sulfinic acid) for the second-order rate constant of C797 with H 2 O 2 was determined to be R110 M À1 s À1 at pH 7.4 ( Figure 2D ).
Together, these data indicate that EGFR C797 is differentiated from the bulk of the cysteine proteome with respect to solvent accessibility, pK a , and H 2 O 2 reactivity.
Activity of the C797S and C797A Mutants In Vitro and in Cells EGFR C797 is the target for a major class of covalent drugs, yet its functional importance in catalysis still remains unknown. Because C797 is located in the hinge region of the ATP-binding pocket, we first characterized the activity of recombinant serine (C797S) or alanine (C797A) EGFR kinase domain (residues 696-1,022). The kinetic parameters for ATP and a peptide substrate were determined using a well-established continuous in vitro kinase assay (Yun et al., 2007) and are summarized in Table 1 (rate plots are presented in Figure S2 ). The catalytic efficiency (k cat / K M ) of the wild-type and mutant kinases is also plotted in Figures  3A and 3B. Overall, the k cat /K M of C797S and C797A was 4.4-to 6.7-fold lower than that of wild-type EGFR. The decreases in k cat / K M were attributable both to lower k cat and higher K M values, with the C797A mutant more affected than C797S. By comparison, the value of k cat /K M for the activating L858R mutant has been reported to be $20-fold higher than that for the wild-type enzyme . In contrast to wild-type EGFR, C797S/A mutants did not exhibit any discernible increase in kinase activity following H 2 O 2 treatment ( Figure S2 ). To place our biochemical findings in a cellular context, plasmids expressing full-length wild-type, C797S, or C797A EGFR were transfected into HeLa cells with low endogenous levels of receptor expression and treated with EGF or H 2 O 2 , followed by western blot and analysis of autophosphorylation (pEGFR) levels. In the absence of EGF, cells transfected by wild-type EGFR displayed a markedly higher level of basal pEGFR compared with C797S/A mutants ( Figures 3C and 3D ). In the presence of EGF, each receptor showed a dose-dependent increase autophosphorylation; however, both mutations diminished the response to EGF with the alanine mutant most severely affected, corroborating our earlier biochemical findings. In addition, H 2 O 2 activation of EGFR was blunted in C797S/A mutants relative to wild-type (Figures 3E, 3F, and S3). Both C797S/A mutants showed little detectable increase in receptor activation compared with corresponding basal levels when cells were exposed to H 2 O 2 at doses of 50, 100 or 250 mM (note that intracellular concentrations of H 2 O 2 are $7-to 10-fold less than the externally applied concentration [Antunes and Cadenas, 2000] ). In contrast to lower exogenous H 2 O 2 doses, treatment of C797S-expressing cells with H 2 O 2 at 500 mM abruptly increased pEGFR levels ( Figures 3E and 3F ). These findings are consistent with other studies showing that exogenous H 2 O 2 concentrations R500 mM broadly inhibit protein tyrosine phosphatases (PTPs), thereby increasing the net level of pEGFR (Garcia and Carroll, 2014; Haque et al., 2011; Leonard et al., 2011; Meng et al., 2002) . Collectively, these data show that C797 is integral for cellular EGFR activity and H 2 O 2 -mediated activation.
Modeling Predicts that C797 Sulfenylation Alters Catalytic Loop Dynamics
To examine possible mechanisms through which sulfenylation of C797 could enhance EGFR kinase activity, we generated a molecular model of sulfenyl C797 (Cys-SOH) based on the wild-type EGFR kinase domain structure. Molecular dynamics (MD) simulations were subsequently performed for reduced and oxidized C797 (Movies S1, S2, S3, and S4). Although C797 predominantly exists as the thiolate anion ( Figure 2C ) or sulfenic acid (pK a $7 in proteins [Gupta and Carroll, 2016a] ) under physiological conditions, calculations were obtained for neutral and deprotonated states for reduced (cysteine -SH and cysteine thiolate -S -) and oxidized (sulfenic acid -SOH and sulfenate -SO -) C797 so as to comprehensively explore potential differences between functional group interactions. The MM-PBSA end-state method was employed to calculate binding free energies of simulated EGFR-ATP complexes. In the reduced (C797-SH and C797-S -) and oxidized (C797-SOH and C797-SO -) forms, EGFR kinase gave estimated interaction energetics similar to those of ATP, suggesting that sulfenyl modification does not have a direct impact on ATP-binding affinity (Table S1 ). Among neutral and deprotonated C797 in reduced and oxidized states, the deprotonated forms of C797 (Cys-S -and Cys-SO -) showed weaker estimated electrostatic interaction with ATP than the neutral states (Cys-SH and Cys-SOH), likely due to close proximity of the negatively charged oxygen atoms of the phosphate tail of ATP (Table S2) .
We also performed hydrogen-bond analysis on the EGFR simulations with various C797 oxidation states. Two cutoff distances (3.0 and 3.5 Å ) were compared (Table S3 ). Deprotonated C797 in reduced and oxidized states (Cys-S -and Cys-SO -) showed more extensive hydrogen bonding with the ribose hydroxyl hydrogen than their corresponding neutral states; however, this extensive interaction does not result in strong affinity with ATP (Table S1 ) and is therefore not likely to account for increased kinase activity. Interestingly, only the sulfenic acid (Cys-SOH) state of C797 was predicted to form new electrostatic interactions with the active site of EGFR. Simulations indicated extensive interaction with the carbonyl backbone oxygen of arginine 841 (R841) via the sulfenyl hydrogen in nearly 50% of trajectories with an average distance of 2.8 Å (Figures 4A and 4B ; Movies S1 and S2). R841 resides in the catalytic loop, a conserved motif (HRDLXXXN) in protein kinases found in subdomain VIb, which positions substrates and conducts catalytic phosphotransfer of ATP to its peptide substrate. Reduced C797 thiol hydrogen interacted only sparsely (<5%) with the backbone carbonyl oxygen of R841 and occurred at distances >3.0 Å (Figures 4A and 4B ). Stronger electrostatic interactions were predicted between C797 sulfenic acid (Cys-SOH) and R841 (À3.5 kcal/mol) than with reduced neutral C797 (À1.4 kcal/mol) and deprotonated C797 (2.4 kcal/mol) (Table S2 ). Other intermolecular interactions (e.g., van der Waals) did not exhibit any significant changes. Finally, when compared with reduced EGFR, the atomic fluctuations of several key regions were affected by oxidation of EGFR C797 to sulfenic acid ( Figure S4 ), including R841 in the catalytic segment, the glycine-rich phosphate-binding loop (P loop), and the activation loop (A loop), which harbors Tyr845, a phosphorylation site. Collectively, our simulations predict that oxidation of EGFR affords new hydrogen-bonding and electrostatic interactions between the C797 sulfenyl hydrogen and R841, which may influence the structural dynamics of several critical regions surrounding the kinase active site.
Catalytic Loop Residue R841 Is Critical for EGFR Function and C797 Sulfenylation
To follow up on our computational studies and probe the functional importance of R841 in redox-based EGFR activation, we (D and F) Densitometric quantification of (C) and (E), respectively. At higher H 2 O 2 concentrations (i.e., 500 mM), C797S phosphorylation levels (##) increase, which can be attributed to PTP inhibition. Data are normalized to untreated wild-type (WT) control and are representative of three independent readings (mean ± SEM). *p < 0.05, ***p < 0.001 compared with untreated wildtype control. replaced this residue with lysine (R841K) or alanine (R841A). Then plasmids expressing wild-type, R841K, or R841A EGFR were transfected into HeLa cells and treated with EGF or H 2 O 2 , followed by western blot and analysis of pEGFR levels. In the absence of EGF, cells transfected by wild-type EGFR gave higher levels of basal pEGFR compared with R841K/A mutants ( Figures 4C and 4D) . Wild-type and R841K/A mutants exhibited EGF-dependent increases in receptor autophosphorylation; however, the pEGFR level for R841K/A mutant kinases was reduced approximately 3-to 5-fold, with the alanine variant being only slightly more affected than the lysine variant. Although autophosphorylation was reduced several fold in R841K/A mutants, H 2 O 2 -mediated activation of these variants was virtually abolished (Figures 4E and 4F) . Consistent with the loss of redox activation, sulfenylation of C797 was essentially non-existent in both R841 mutants compared with the response observed for wild-type EGFR ( Figure S3 ). Together with our MD simulations, our functional studies identify R841 as important for kinase activity, and that this residue may facilitate C797 sulfenylation or help to stabilize the sulfenic acid modification at this site.
Oncogenic EGFR Mutants Exhibit Different Redox Sensitivity
Given the profound effect that protein environment can have on cysteine oxidation, we next wondered whether C797 shows altered redox sensitivity in frequently occurring oncogenic EGFR mutants (L858R/T790M and D746-750). To examine this question, we stimulated adenocarcinomic human alveolar basal epithelial cell lines A549 (wild-type EGFR), NCI-H1875 (L858R/ T790M EGFR), and HCC827 (D746-750 EGFR) with EGF and probed for kinase sulfenylation. EGF-mediated sulfenylation was detectable in oncogenic mutants as well as wild-type, although basal oxidation levels (i.e., minus EGF) differed among these kinases (Figures 5A-5C ). Of note, the dose-dependent change in sulfenylation of EGFR was greatest in the L858R/ T790M mutant compared with wild-type and the deletion mutant, D746-750 ( Figure 5D ). In the case of wild-type and D746-750 EGFR, peak sulfenylation was observed at 4 ng/ml EGF, while oxidation of L858R/T790M was greatest at 5-fold higher growth factor (i.e., 20 ng/ml). Given the location of L858R/T790M with respect to C797, these two point mutations may alter structural and electrostatic features of the kinase active-site pocket, leading to different redox sensitivity. Overall, these data suggest that clinically relevant oncogenic EGFR mutants can exhibit unique cysteine sulfenylation profiles.
Chronic H 2 O 2 Stress Alters the Pharmacology of Irreversible EGFR Inhibitors Covalent EGFR inhibitors with acrylamide ''warheads'' irreversibly bind to C797 through Michael addition to the reduced form of the kinase (Singh et al., 2010) . Of these, the most well known are based on the 4-anilinoquinazoline scaffold, which targets this inhibitor class to the EGFR active site for covalent reaction with the C797 thiol (Singh et al., 1997) . Due to the nature of this chemical reaction, oxidation of C797 to any redox form (e.g., -SOH and/or -SO 2 H and/or -SSG) is expected to affect the pharmacology of such acrylamide-based inhibitors. To investigate the effect of chronic oxidative stress on inhibitor potency in a cellular context we used two 4-anilinoquinazoline inhibitors, afatinib (Li et al., 2008) and PD168393 (Fry et al., 1998) (Figure 1B ). For simulation of chronic oxidative stress, glucose oxidase was added to the medium at a non-toxic dose (2 U/ml) to generate an intracellular steady-state level of H 2 O 2 of 1-2 mM, as previously described (Askoxylakis et al., 2011; Long et al., 2012; Millonig et al., 2009; Mueller et al., 2009 ). Following a 3-hr exposure to H 2 O 2 (via the glucose oxidase system) and 1-hr inhibitor treatment, cells were stimulated with EGF and analyzed for changes in EGFR autophosphorylation. In the absence of oxidative stress, EGFR was inhibited by >95% at 1 mM afatinib or PD169383 (Figures 6A and 6B ; western blots depicted in Figure S5 ). In the presence of H 2 O 2 , potency was demonstrably reduced at inhibitor concentrations of 1 mM and above, with an apparent leveling off of the dose response at $25% pEGFR. At doses R10 mM, incomplete inhibition by either compound (Figures 6A and 6B) reflects a population of EGFR, which has been rendered resistant to irreversible targeting.
DISCUSSION
Cysteine oxidation modulates kinase activity during intracellular signal transduction Carroll, 2012, 2013) . Coupled with our earlier findings that sulfenylation of C797 enhances catalytic activity with GST-tagged EGFR kinase domain in a peptide assay, our findings using native EGFR demonstrates that exposure to physiological concentrations of H 2 O 2 leads to sulfenylation of C797 and enhanced receptor autophosphorylation in cells (Figure 1 ). The location of C797 with respect to the C helix and catalytic loop raises the possibility that new interactions made possible through C797 sulfenylation may lead to transition-state stabilization or destabilization of its autoinhibitory conformation . EGFR C797 is located at the amino terminus of an a helix, also referred to as the N cap position. Cysteines are the most sparsely occurring N cap residue, comprising <1% of this position (Penel et al., 1999) . Even so, N cap cysteines are enriched among redox-active proteins, like human thioredoxin. The alignment of peptide-bond dipole moments within an a helix generates a macroscopic dipole along the helical axis, and negatively charged residues are often found at the amino termini where they have a stabilizing interaction with the positive charge of the helix dipole. At this unique structural position, electrostatic interactions of the thiol with the helix dipole can lower its pK a and increase the susceptibility of this residue to oxidation 
. The Effect of Chronic Oxidative Stress on Irreversible EGFR Inhibitors and Model for Redox Regulation of EGFR in Cells
(A and B) A431 cells were incubated with 2 U/ml glucose oxidase for 3 hr to simulate chronic H 2 O 2 stress, treated with (A) afatinib or (B) PD168393 for 1 hr, and subsequently treated with 100 ng/ml EGF for 5 min. Plots represent densitometric quantification of western blotting for phosphorylated (p) and total EGFR. Data are normalized to untreated control for each respective condition and are representative of two independent readings (mean ± SEM) (C) Model for H 2 O 2 modification of EGFR C797 in cells. (Anderson and Sauer, 2003; Miranda, 2003) . Consistent with this prospect, we determined that EGFR C797 has a pK a of 5.5 ± 0.1 (nearly three orders of magnitude lower than the pK a of free cysteine sulfhydryl in solution) and a lower limit for H 2 O 2 reactivity of R110 M À1 s À1 (more than two orders of magnitude higher than GSH and at least 5-fold more reactive than the protein tyrosine phosphatase, PTP1B ). Using selective cell-permeable chemical probes, direct evidence for H 2 O 2 generation with EGFR stimulation in A431 cells was first provided by Miller et al. (2007) . In A431 cells, the average number of EGFRs at the cell surface corresponds to $640/mm 2 or approximately 1.2 3 10 6 receptors per cell (Zhang et al., 2015) . Given the inhomogeneous and two-dimensional nature of the plasma membrane, extrapolating these values to reflect a three-dimensional environment is difficult. With this caveat in mind, a back-of-the-envelope calculation using the aforementioned values suggests a lower limit for receptor concentration of around 1 mM. With this estimated concentration and known second-order rate constants, the ratio ( and existence of receptors within networks of high-density membrane patches (i.e., R1 mM). Once the C797 thiolate is sulfenylated by H 2 O 2 , with GSH supplying the reducing equivalents, at steady state the cellular half-life of EGFR C797-SOH is estimated to be $12 min ( Figure 6C ). This figure correlates well with our observation that global protein sulfenylation peaks $5 min after EGF addition to cells, with a subsequent decay over 30 min . As an alternative to GSH restoring sulfenylated receptor back to its reduced state, EGFR C797-SOH can be oxidized further to sulfinic acid (-SO 2 H), which is generally an irreversible modification in biological systems (Lo Conte and Carroll, 2012; Lo Conte and Carroll, 2013; Lo Conte et al., 2015) . Although not explicitly measured in this work for EGFR, rates of sulfinic acid formation are typically 10-to 1,000-fold slower than for the equivalent thiolate owing to the reduced nucleophilic character of sulfur in the sulfenic acid state Lo Conte and Carroll, 2013; Paulsen and Carroll, 2013) . With this approximation, the rate constant for sulfenylation of EGFR is anticipated to be $0.1-10 M À1 s À1 ( Figure 6C ). For this reason, it is unlikely that any significant amount of overoxidized EGFR C797 is generated in a normal cellular environment. In short, our observation of EGFdependent sulfenylation of EGFR in cells is fully compatible with the physical and reactivity properties of C797 observed in our biochemical experiments. C797 mutants exhibit altered autophosphorylation and sulfenylation properties upon cell stimulation (Figure 3 ) and have lowered catalytic efficiency (k cat /K M ) compared with wild-type EGFR ( Table 1 ). The behavior of C797S/A mutants in biochemical and cellular studies supports a model wherein C797 functions as a redox switch to stimulate EGFR autophosphorylation. Using computational modeling, we identified an arginine residue, R841, that is predicted to have enhanced intermolecular interactions due to hydrogen bonding with the sulfenic acid form of C797 (Tables S1-S3 and Figure 4 ). R841 is a highly conserved residue found in the catalytic loop of the tyrosine kinase family that plays a role in coordinating the phosphate tail and associated Mg 2+ ions (Gajiwala et al., 2013) . Therefore, oxidation of C797 has the potential to influence catalytic loop dynamics (Figures 4 and S4; Movie S1). Hydrogen bonding between sulfenyl C797 and the backbone carbonyl of R841 could stabilize the greater catalytic loop, facilitating metal ion coordination and overall interactions with the ATP phosphate tail, ultimately stimulating kinase activity. From a more granular molecular perspective, new electrostatic interactions between R841 and ATP substrate might position the positively charged guanidinium group near the bridging oxygen between the b-and g-phosphates to stabilize the negative charge that builds up on this oxygen as the nucleophile attacks. Our simulations are in good agreement with the determined kinetic parameters of the C797 mutants, where ATP-binding affinity (K M ) is modestly affected while turnover (k cat ) is affected to a greater extent (Table 1) . Interestingly, sequence alignment reveals that some kinases such as c-Src and b-Raf contain a serine at the position corresponding to EGFR C797. From this standpoint, the hydroxyl side chain of serine may participate in interactions with R841, analogous to C797-SOH, and could account for the increased reactivity of EGFR C797S compared with C797A observed in cells. The competence of EGFR C797S, relative to C797A, is also underscored by the recent findings that this mutation is acquired in NSCLC patients who developed resistance to the irreversible inhibitor, AZD9291 (Thress et al., 2015) . We also determined whether commonly occurring oncogenic EGFR mutations (L858R/T790M and D746-750) affected their propensity to undergo sulfenylation. Given their relative proximity to the active site and C797, the L858R/T790M mutant was of particular interest, whereas D746-750 is more distal and might be expected to have little to no effect on sulfenylation ( Figure 1A ). Our findings indicate that the L858R/T790M mutations correlate with an increased propensity to undergo sulfenylation compared with the D746-750 mutant ( Figure 5 ). In this context, structural rearrangements and increased positive electrostatic potential stemming from the L858R mutation may facilitate reaction of the C797 thiolate with H 2 O 2 . In addition, the T90M mutation causes an increase in the frequency of activesite opening (i.e., movement between the N and C lobes), which would increase the solvent accessibility of the active site and C797. Another interesting finding from these experiments is that basal levels of sulfenylation were consistently higher in oncogenic mutants relative to wild-type EGFR. An increase in the steady-state population of sulfenylated C797 is relevant to the overall kinase activity of EGFR and may also affect the pharmacology of irreversible inhibitors designed to target these resistance mutations in EGFR-driven cancer cells.
The concentration of H 2 O 2 in transformed cells is dependent upon the cancer cell type, oxygen tension, and expression of scavenger enzymes. Notwithstanding this variation, the steady-state level of H 2 O 2 in cancer cells has been shown to increase by as much as 40-fold compared with their non-transformed counterparts (Spitz et al., 2012) . Given an intracellular H 2 O 2 concentration of $10-50 nM in normal tissue (Sies, 2014; Winterbourn, 2013) , this would translate into $0.4-2 mM in cancer cells. Another study in cancer cells across a range of tumor types indicates that rates of H 2 O 2 production are comparable in magnitude with the respiratory burst in human neutrophils (Szatrowski and Nathan, 1991) , corresponding to an intracellular steady-state H 2 O 2 concentration of $1-4 mM. While these concentrations assume a homogeneous distribution of H 2 O 2 across the cell, it is increasingly appreciated that diffusion of H 2 O 2 across the cytoplasm is limited (Dickinson and Chang, 2011; Mishina et al., 2011) . Instead, H 2 O 2 localizes to microdomains near the sites of its generation during RTK signaling (Holmstrom and Finkel, 2014) . Thus, the H 2 O 2 concentration near the signalsome formed by activated EGFR may be higher than the aforementioned values. At steady state, we estimate that the fraction of EGFR C797 in the sulfenic acid form in cancer cells could reach $0.2 or 20% (concentrations and rate constants: EGFR, 1 mM and 110 M À1 s À1 ; GSH, 1 mM and 0.89 M À1 s
À1
; H 2 O 2 , 2 mM). Note that our estimate infers site-localized oxidation of EGFR at the plasma membrane where reactive peroxidases, such as peroxiredoxins, are either absent or have been inactivated through hyperoxidation (Wood et al., 2003) or phosphorylation (Woo et al., 2010) .
As discussed above, deregulation of EGFR signaling is prevalent in human cancers and has motivated the development of inhibitors that target EGFR C797 (Liu et al., 2013) . Under chronic H 2 O 2 -induced oxidative stress (1-2 mM intracellular H 2 O 2 ), we observed a leveling off of the dose response around $25% pEGFR for both afatinib and PD168393 ( Figures 6A and 6B) . Incomplete inhibition by these inhibitors is indicative of an oxidized population of EGFR, which does not undergo covalent adduction by thiol-targeted electrophiles. Along these lines, a separate study has demonstrated that glutathionylation of C797 can also diminish the potency of covalent EGFR inhibitors (Schwartz et al., 2014) . Although the authors of this study generated glutathionylated EGFR in vitro through incubation of the C797 thiolate with oxidized GSH (GSSG), the kinetically competent and more probable pathway for glutathionylation in vivo would be attack of GSH on the C797-SOH oxoform ( Figure 6C ). Regardless, from our collective studies it is clear that cysteine oxidation can alter kinase active-site topography, affect the activity of reversible and irreversible covalent inhibitors designed to target wild-type EGFR, and likely contribute to mechanisms of drug resistance.
In patients with advanced solid tumors, the recommended daily dose of afatinib (40 mg orally once daily) gives a mean maximum plasma concentration (C max ) value at steady state of 38.0 ng/ml or $80 nM (Wind et al., 2013) . The effectiveness of afatinib against EGFR has also been reported (Schwartz et al., 2014) : k inact /K i * $2 3 10 5 M À1 s À1 (Kinetic parameters: k inact $2 3 10 À3 s À1 and K i * $4.4 nM). This second-order rate constant is $2,000-fold higher than the reactivity of H 2 O 2 with EGFR C797. Then again, the plasma concentration of afatinib is $25-fold less than the level of H 2 O 2 estimated in cancer cells ($2 mM) and ostensibly lower at the site of action, leading to a reactivity differential of 75-fold or less. If new EGFR is resynthesized in the presence of afatinib and H 2 O 2 (depending upon cell type, the half-life of EGFR is 8-24 hr [Sorkin and Duex, 2010] ), it is expected that alkylation of C797 would predominate. However, this analysis does not take into account the low specific chemical reactivity between afatinib and C797. In other words, afatinib may bind to EGFR with high reversible binding affinity, but the ensuing Michael reaction is extremely slow. In this scenario, H 2 O 2 could oxidize C797 in the noncovalent EGFR-drug complex and the competition between afatinib and H 2 O 2 modification could be less than or equal to 10:1 (k inact $2 3 10 À3 s À1 versus k ox $2 3 10 À4 s À1 ). Interestingly, afatinib has a long terminal elimination half-life (37.2 hr at steady state), supporting a once-daily dose regimen (Wind et al., 2013) . Higher doses are often associated with adverse events, such as diarrhea and rash. Therefore, it is unlikely that the efficacy of afatinib could be increased significantly either through increased dosage or altered frequency. The susceptibility of EGFR C797 to oxidation and its mutation to serine in NSCLC patients treated with AZD9291 highlight the ongoing need to develop novel strategies and combination therapies to inhibit EGFR signaling. Toward this end, the sulfenic acid modification is a unique functional group in the cellular milieu and may afford a new opportunity in inhibitor design, where nucleophilic ''warheads'' Carroll, 2016a, 2016b ) are appended to existing or novel inhibitor scaffolds and to target the sulfur atom in its oxidized state. In this approach, the propensity of H 2 O 2 -sensitive cysteines in kinases and other proteins of therapeutic interest, such as tyrosine phosphatases, can be exploited to develop new classes of inhibitors akin to proof-of-concept studies reported earlier by our group (Garcia and Carroll, 2014; Leonard et al., 2011) .
Finally, kinases containing a cysteine that is structurally homologous to C797, including Her2 and BTK, represent another critical area of future research. In addition, more than 150 kinases contain a cysteine in or around the nucleotide-binding site, where oxidation has the potential to affect both function and drug pharmacology . Of these 150 kinases, in recent proteomic studies we have mapped redox-active cysteine residues in GAK, MAP2K1, -3, -4, PBK, PRK, and ZAK (Yang et al., 2014) and FAK, LIM, and NEK (Gould et al., 2015) . Given the findings of this work, our recent proteomics analyses, and the clinical importance of this class of enzymes, it remains a high priority to delineate the full scope of the redox-modified and redox-regulated kinomes.
SIGNIFICANCE
Hydrogen peroxide is generated as a signaling molecule in a wide variety of signal transduction pathways and is intimately involved in cell-fate decisions. The mechanism of ''redox signaling'' includes H 2 O 2 -mediated oxidation of reactive cysteines to rapidly and reversibly alter protein activity, stability, localization, and interactions. This study provides, for the first time, a molecular understanding of how cysteine sulfenylation (Cys-SOH) can augment protein kinase activity as well as affect inhibitor pharmacology in cells. We expect that this work will lay the foundation to further elucidate redox-regulatory mechanisms in the kineome, and to develop a new class of therapeutics that targets cysteine residues in their sulfenylated form.
EXPERIMENTAL PROCEDURES
General Reagents and Methods EGF (BD Biosciences) and H 2 O 2 (Sigma) were prepared in ddH 2 O. DYn-2 (R99% purity) was synthesized as previously described and prepared in 250 mM DMSO . 250 mM dimedone (Sigma) was prepared in 500 mM 70% DMSO/30% Bis-Tris (pH 7.4). 20,000 U/ml catalase (Sigma) and 500 U/ml glucose oxidase (Sigma) were prepared fresh in 50 mM Tris-HCl (pH 7.4). 5 mM azide biotin (Invitrogen) and 5 mM TAMRA azide (Invitrogen) were prepared in DMSO. 100 mM BTTP (Kerafast) was prepared in DMSO, and stock dilutions were prepared with ddH 2 O. Sodium L-ascorbate (Sigma) and CuSO 4 (Sigma) were prepared fresh in ddH 2 O. 10 mM afatinib (ChemieTek, R99% purity) and 10 mM PD168393 (Santa Cruz Biotechnology, R95% purity) stocks were prepared in DMSO.
Cell Culture
Cell lines (American Type Culture Collection) were maintained at 37 C in a 5% In Vitro EGFR Autophosphorylation Assay A431 cells were serum-starved for 2 hr, washed with cold PBS (23), and lysed in RIPA B buffer as described below. Native full-length EGFR was immunoprecipitated from 1,000 mg (1 mg/ml) with 40 ml of goat anti-EGFR conjugated agarose for 30 min at 4 C with rocking. Resin was collected by centrifugation, washed with cold RIPA B buffer (33), and resuspended in 100 ml of 40 mM HEPES (pH 7.4). EGFR autophosphorylation was assayed from 50 mg of lysate in 10-ml reactions containing 20 mM HEPES (pH 7.4), 6 mM MnCl 2 , 100 mM NaVO 4 (New England Biolabs), and 1 mM ATP (Promega) and supplemented with EGF (3.3 ng/ml) or H 2 O 2 (0-100 mM). EGF-treated reactions were initiated by the addition of immunoprecipitated EGFR and incubated on ice for 5 min. 
EXPERIMENTAL PROCEDURES

Cloning of EGFR C797 and R841 Mutants
Wild type EGFR in pCMV6-XL4 was obtained from Origene. C797S was generated by site-directed mutagenesis with the following primers: 5'-CATGCCCTTCGGCTCGCTCCTGGACTATG-3' and 5'-CATAGTCCAGGAGCGAGCCGAAGGGCATG-3'. C797A was generated with the following primers: 5'-CATGCCCTTCGGCGCCCTCCTGGACTATG-3' and 5'-CATAGTCCAGGAGGGCGCCGAAGGGCATG-3'. R841K was generated by site-directed mutagenesis with the following primers: 5'-CGACCTGGCAGCCAAGAACGTACTGGTG-3' and 5'-CACCAGTACGTTCTTGGCTGCCAGGTCG-3'. R841A was generated with the following primers: 5'-CGACCTGGCAGCCGCGAACGTACTGGTG-3' and 5'-CACCAGTACGTTCGCGGCTGCCAGGTCG-3'.
Cloning, Expression, and Purification of EGFR Kinase Domain
Wild type, C797S, and C797A EGFR (residues 696-1022) in pFastBac was obtained from Blue Sky BioServices. EGFR kinase domain constructs were expressed and purified using a baculovirus/insect cell system by Blue Sky BioServices. The protein was concentrated to 5 mg/ml and stored in 50 mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM DTT, and 20% glycerol.
Measurement of EGFR C797 pK a
A 100 µL solution of recombinant EGFR (10 µM) in 100 mM phosphate buffer at 9 different pH values (2.19, 2.83, 3.22, 3.78, 4.06, 4.77, 5.16, 5 .82 and 6.52) was plated in a black, round-bottom 96-well plate (Costar 3792) and 9-bromobimane (Sigma) was added at a concentration of 32 µM (8 equivalents). The plate was immediately placed in the SpectraMax (Molecular Devices) reading chamber and the fluorescence signal resulting from the formation of alkylation adduct was measured after 10 min (λ exc = 390 nm; λ em = 465 nm). The wells containing bromobimane in buffer at respective pH values with no EGFR served as background signal. To verify if the fluorescent signal at low pH values resulted from predominant labeling of EGFR C797, a control experiment was performed where 100 µM EGFR was incubated with 1 mM of PD168393 compound for 90 min under the conditions reported earlier by Fry et. al. in order to form a covalent adduct between PD168393 and EGFR C797 quantitatively. C797-labeled EGFR was then diluted with 100 mM phosphate buffer at different pH values and reacted with 9-bromobimane following the exact same protocol mentioned above. Again, the wells with no EGFR served as background signal. The background corrected relative fluorescence units (RFU) were then plotted against pH and the data was fit by nonlinear regression model to obtain pK a value using the equation:
(1 + 10 +,%-+. )
Measurement of EGFR C797 Reactivity with H 2 O 2
Recombinant EGFR was dialyzed for 4 h in 2 L of 100 mM phosphate buffer at pH 7.4 (buffer switched after 3 h) using 0.1-0.5 mL Slide-A-Lyzer cassette (ThermoFisher) with 10K molecular weight cutoff to remove DTT. The dialyzed EGFR was then diluted to 4 µM with 100 mM phosphate buffer at pH 7.4 and pre-reduced with 8 µM of TCEP-HCl (Sigma) for 30 min at 4 ºC. The pre-reduced EGFR was then aliquoted in four 100 µL aliquots and incubated with 10, 20, 40 and 80 µM H 2 O 2 , respectively. At periodic intervals (5, 10, 15 and 20 min), 20 µL aliquots form these reactions were quenched with 2 µL of 20,000 unit/mL catalase solution for 5 min. The sulfenic acid formed by H 2 O 2 treatment was trapped by reacting with 500 µM of Dyn-2 probe pre-clicked with TAMRA azide (Lumiprobe) for 2 h. Aliquots of these reactions were then quenched by addition of 2X Laemmli buffer and heating at 95 ºC for 5 min. The labeled EGFR samples were then subjected to in-gel fluorescence analysis. Briefly, they were separated by SDS-PAGE using NuPAGE Novex 4-12% Bis-Tris Midi gels. The gels were destained 2X (40% methanol, 10% acetic acid, 50% H2O) and 1X with water for 10 min to remove background fluorescence. The gels were analyzed using a Typhoon 9400 variable mode imager (Amersham Biosciences) using excitation and emission wavelengths of 550/580 nm (TAMRA) and 450/610 nm (SYPRO). The RFU signal was then plotted against time to obtain k obs at different H 2 O 2 concentrations using the standard first-order rate equation. The k obs was then plotted against H 2 O 2 concentration to obtain the second order rate constant for EGFR C797 sulfenylation.
In Vitro EGFR Tyrosine Kinase Assay Steady-state kinetic parameters were determined in triplicate using the ATP/NADH coupled enzyme assay system in a 384-well format (Barker, et al., 1995) . The reaction mixture contained 0.5 mg/ml BSA, 2 mM MnCl 2 , 1 mM phospho(enol) pyruvic acid (PEP; Sigma Aldrich, # P7002), 1 mM TCEP (Sigma Aldrich), 0.1 M MOPS pH 7.5,
